Patents by Inventor Ivan Nemazanyy

Ivan Nemazanyy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN
    Publication number: 20170145391
    Abstract: The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.
    Type: Application
    Filed: February 2, 2017
    Publication date: May 25, 2017
    Applicants: Ludwig Institute for Cancer Research, UCL Business PLC
    Inventors: Ivan Nemazanyy, Ganna Panasyuk, Alexander Zhyvoloup, Michael Waterfield, Ivan Gout
  • TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN
    Publication number: 20140120099
    Abstract: The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.
    Type: Application
    Filed: September 24, 2013
    Publication date: May 1, 2014
    Applicants: UCL Business PLC, Ludwig Institute for Cancer Research
    Inventors: Ivan Nemazanyy, Ganna Panasyuk, Alexander Zhyvoloup, Michael Waterfield, Ivan Gout
  • Truncated variant of the mammalian target for rapamycin (MTOR) protein
    Patent number: 8669347
    Abstract: The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: March 11, 2014
    Assignees: UCL Business PLC, Ludwig Instituted for Cancer Research
    Inventors: Ivan Nemazanyy, Ganna Panasyuk, Alexander Zhyvoloup, Michael Waterfield, Ivan Gout
  • TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (MTOR) PROTEIN
    Publication number: 20100247542
    Abstract: The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.
    Type: Application
    Filed: May 1, 2008
    Publication date: September 30, 2010
    Inventors: Ivan Nemazanyy, Ganna Panasyuk, Alexander Zhyvoloup, Michael Waterfield, Ivan Gout